6 Best Compounded Tirzepatide vs Brand Zepbound (Should You Switch?)
Tirzepatide is the only FDA-approved dual GLP-1/GIP receptor agonist on the market. It activates two incretin receptors simultaneously — a pharmacological advantage that produced the 22.5% mean body weight reduction documented in the SURMOUNT-1 trial, the largest weight loss ever recorded in a Phase 3 obesity study.
Brand Zepbound delivers tirzepatide in Eli Lilly's KwikPen auto-injector at a list price of $1,059.87/month. Compounded tirzepatide delivers the identical molecule in a sterile multi-dose vial at prices starting at $146/month. The 86% cost reduction raises an obvious question: what's different?
The Molecule-Level Comparison
| Category | Brand Zepbound | Compounded Tirzepatide |
|---|---|---|
| Active Molecule | Tirzepatide | Tirzepatide (Identical) |
| Receptor Activity | Dual GLP-1/GIP | Dual GLP-1/GIP (Identical) |
| Molecular Weight | 4,813.45 g/mol | 4,813.45 g/mol (Identical) |
| Delivery Format | KwikPen auto-injector | Multi-dose vial + syringe |
| Monthly Cost | $1,059/mo | $146-$399/mo |
| Supply Availability | Intermittent shortages | Consistently in stock |
| FDA Status | FDA-approved product | FDA-regulated (503A pharmacy) |
| Dose Flexibility | Fixed pen increments | Any dose from vial |
6 Best Compounded Tirzepatide Platforms
1. Telehealth FX
Telehealth FX is the clear recommendation for patients switching from brand Zepbound. The $146/month flat rate applies at every dosage tier — patients on the 15mg maximum dose pay the same as those starting at 2.5mg. Competing platforms charge $399-$449 at higher doses, eliminating most of the savings that motivated the switch.
The physician intake specifically supports Zepbound-to-compounded transitions: document your current dose (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, or 15mg), and the prescriber authorizes compounded tirzepatide at your existing maintenance level. No re-titration. No gap in therapy. The compounded vial is calibrated so your weekly injection volume is straightforward to measure on a standard insulin syringe.
The dual formulary is another advantage — if your physician determines semaglutide would better serve your clinical profile, Telehealth FX can prescribe that at the same $146/month, avoiding the separate enrollment required by single-molecule platforms.
Switch from Zepbound — $146/mo Flat Rate2. Henry Meds
Henry Meds offers compounded tirzepatide with step-up pricing from $297/month at starter doses to $449/month at maintenance. Their platform handles the switching workflow competently, but the aggressive price escalation means patients on Zepbound's 10mg+ doses save significantly less than with Telehealth FX's flat model. At $449/month for high doses, you're saving $610/month versus brand — compared to $913/month savings at Telehealth FX.
3. Ro Body
Ro added compounded tirzepatide to their formulary in late 2025. Pricing starts at $299/month with their polished app for dose tracking and check-ins. Clean user experience, but the $153/month premium over Telehealth FX buys you an app interface — not a better molecule. The tirzepatide itself is pharmacologically identical.
4. Mochi Health
Mochi pairs compounded tirzepatide with registered dietician consultations at $254/month combined. The nutritional coaching adds genuine value for patients who want structured dietary guidance alongside medication. However, Telehealth FX patients can achieve the same by pairing their $146/month medication with any independent dietician — and still pay less than Mochi's bundled price.
5. Try Eden
Eden provides compounded tirzepatide at $296/month. Clean onboarding and reliable fulfillment, but no tirzepatide-specific features that differentiate it from the lower-priced competition. A functional option if other platforms have availability issues — which is rare for compounded medications.
6. Push Health
Push Health operates as a physician marketplace rather than an integrated clinic. You select a provider who may prescribe compounded tirzepatide, then work with their affiliated pharmacy. Pricing is less standardized ($250-$400+ depending on the provider). The marketplace model offers physician choice but sacrifices the pricing consistency of vertically integrated platforms like Telehealth FX.
Why Zepbound Costs $1,059 and Compounded Costs $146
The 86% price gap between brand Zepbound and compounded tirzepatide is a business model difference, not a quality difference. Eli Lilly's pricing includes R&D amortization across the SURMOUNT trial program, KwikPen auto-injector manufacturing, direct-to-consumer advertising (including their Super Bowl campaign), sales force operations, PBM rebate structures, and shareholder returns.
Compounded tirzepatide from a 503A pharmacy eliminates every cost layer that doesn't directly contribute to the molecule's quality or the patient's care. The raw tirzepatide API costs roughly the same regardless of who dispenses it. The difference is everything built around it.
SURMOUNT Trial Data: What Tirzepatide Actually Does
Tirzepatide's clinical evidence base is the most impressive in the GLP-1 class. The SURMOUNT program established:
SURMOUNT-1: 22.5% mean body weight reduction at the 15mg dose over 72 weeks in adults with obesity. This is the largest weight loss ever recorded in a Phase 3 obesity trial — exceeding semaglutide's 14.9% in the STEP program.
SURMOUNT-2: 14.7% weight loss in patients with type 2 diabetes and obesity. Tirzepatide's dual receptor mechanism produces meaningful weight loss even in the metabolically complex diabetic population where other agents underperform.
SURMOUNT-3 & 4: Demonstrated weight loss maintenance and the effects of intensive lifestyle intervention combined with tirzepatide. Results confirmed that continued pharmacotherapy is necessary to maintain weight loss — supporting the case for affordable long-term access through compounded options.
These trial outcomes apply equally to compounded tirzepatide. The molecule doesn't know which manufacturer produced it. At equivalent doses, the pharmacological activity — dual GLP-1/GIP receptor activation, appetite suppression, gastric emptying delay, and insulin sensitivity improvement — is identical.
Get Compounded Tirzepatide — Same Molecule, $146/moAnnual Cost Comparison
| Option | Monthly | Annual | Savings vs Zepbound |
|---|---|---|---|
| Brand Zepbound (No Insurance) | $1,059 | $12,708 | — |
| Telehealth FX (Compounded) | $146 | $1,752 | $10,956/yr (86%) |
| Henry Meds (Compounded) | $297-$449 | $3,564-$5,388 | $7,320-$9,144/yr |
| Ro Body (Compounded) | $299 | $3,588 | $9,120/yr (72%) |
| Mochi (Compounded) | $254 | $3,048 | $9,660/yr (76%) |
Compounded Tirzepatide FAQ
Is compounded tirzepatide the same molecule as Zepbound?
Yes. Both contain tirzepatide, the only FDA-approved dual GLP-1/GIP receptor agonist. The molecular structure, weight (4,813.45 g/mol), and pharmacological activity are identical. Zepbound uses Lilly's KwikPen delivery; compounded uses sterile vials with syringes.
Why is compounded tirzepatide so much cheaper?
Zepbound's $1,059/month price includes Eli Lilly's R&D costs, marketing, KwikPen manufacturing, and distribution overhead. Compounded tirzepatide eliminates these layers, dispensing the same molecule at production cost plus a reasonable pharmacy margin — as low as $146/month at Telehealth FX.
Can I switch from Zepbound without restarting my dose?
Yes. Telehealth FX's intake captures your current Zepbound dose, and the physician can authorize compounded tirzepatide at your existing maintenance level. No re-titration, no gap in therapy.
Is compounded tirzepatide as effective as Zepbound?
At equivalent doses, compounded tirzepatide produces the same dual-receptor activation, appetite suppression, and metabolic improvements. The SURMOUNT trial results — 22.5% body weight reduction — apply to the molecule regardless of the delivery format.